Related Experiment Videos
The management of bacterial meningitis in children
Trevor Duke1, Nigel Curtis, David G Fuller
1Centre for International Child Health, University Department of Paediatrics, Royal Children's Hospital, Flemington Road, Parkville, Victoria, 3052, Australia. trevor.duke@rch.org.au
Insights
Bacterial meningitis remains a critical global health issue, particularly in developing nations. Effective treatment and prevention strategies, including vaccines and affordable antibiotics, are crucial to reduce child mortality and disability.
Area of Science:
- Pediatrics
- Infectious Diseases
- Global Health
Background:
- Bacterial meningitis is a leading cause of childhood death and disability globally.
- Disease burden is shifting to developing countries due to vaccine affordability issues.
- Antimicrobial resistance is complicating treatment in both developed and developing nations.
Purpose of the Study:
- To review the current challenges and potential solutions for bacterial meningitis in children worldwide.
- To assess the role of vaccines, antibiotics, and adjuvant therapies in managing bacterial meningitis.
- To highlight the disparities in access to care and effective treatments between developed and developing countries.
Main Methods:
- Literature review of bacterial meningitis epidemiology, treatment, and prevention.
- Analysis of antibiotic resistance patterns and their impact on therapeutic choices.
- Evaluation of evidence for adjuvant therapies, such as corticosteroids, in managing meningitis.
Main Results:
- Increasing antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae compromises treatment efficacy in resource-limited settings.
- High case fatality rates (up to 50%) and neurological sequelae (one-third of survivors) are reported.
- Corticosteroid effectiveness is most evident with specific pathogens (H. influenzae type b), early administration, and bactericidal antibiotics.
Conclusions:
- Vaccine availability for all major pathogens is essential for long-term control of bacterial meningitis.
- Affordable access to third-generation cephalosporins in developing countries is a critical intervention.
- Addressing healthcare access, late presentation, and antimicrobial resistance are key to improving outcomes.
Abstract:
Bacterial meningitis is still a major cause of death and disability in children worldwide. With the advent of conjugate vaccines against the three major pathogens, the burden of disease is increasingly concentrated in developing countries that cannot afford the vaccines. Antibiotic resistance is an increasing problem; in developed countries, high-level resistance to beta-lactams among Streptococcus pneumoniae necessitates the addition of vancomycin to third-generation cephalosporins. In many developing countries, the problems are more fundamental. Increasing resistance of S. pneumoniae to penicillin and chloramphenicol and of Haemophilus influenzae to chloramphenicol means that many children with bacterial meningitis receive ineffective treatments, as third-generation cephalosporins are often unavailable or unaffordable. Case fatality rates are as high as 50% and neurological sequelae occur in one-third of survivors. The use of corticosteroids in meningitis is controversial; the evidence that they protect against neurological complications of childhood meningitis (particularly severe hearing loss) is strongest when: meningitis is caused by H. influenzae type b; dexamethasone is given before the first dose of antibiotics; a bactericidal antibiotic such as a third-generation cephalosporin is used; and in the early stages of the infection. There are few controlled clinical trials on which to base recommendations about other adjuvant therapy for meningitis. Avoidance of secondary brain injury from hypoxia, hypotension, hypo-osmolarity and cerebral oedema, hypoglycaemia or convulsions is essential for a good outcome. The problem of bacterial meningitis will only be solved if protein-conjugate vaccines (or other effective vaccine strategies) against S. pneumonia, H. influenzae and epidemic strains of Neisseria meningitidis are available to all the world's children. Making third-generation cephalosporins affordable in the developing world is also a necessary intervention, but better antibiotics will not overcome the problems of poor access to hospitals and late presentation with established brain injury, and will inevitably bring further pressure for antimicrobial resistance.